ACE and COVID-19: Since the beginning of the COVID-19 pandemic, the use of ACE inhibitors and ARBs in hypertensive patients with COVID-19 has been controversial due to the proven role of RAS in regulating blood pressure mechanisms and the role of ACE2 receptors as an entry gate to SARS-CoV-2 [28].